Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3384886 | 0.92 | HPRT1 (0.45) | PAX8HSD17B10CYP2A6TDP1ALDH1A1 | |
| SCHEMBL994780 | 0.86 | PAX8 (0.38) | PAX8HSD17B10CYP2A6TDP1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL25188851 | 0.84 | PAX8 (0.37) | PAX8HSD17B10CYP2A6TDP1ALDH1A1 | |
| SCHEMBL23840 | 0.75 | ALDH1A1 (0.47) | PAX8HSD17B10CYP2A6TDP1ALDH1A1 | |
| SCHEMBL5313840 | 0.75 | ALDH1A1 (0.47) | PAX8HSD17B10CYP2A6TDP1ALDH1A1 | |
| SCHEMBL2479044 | 0.73 | CYP2A6 (0.44) | PAX8HSD17B10CYP2A6TDP1ALDH1A1 | |
| SCHEMBL21805847 | 0.73 | ALDH1A1 (0.44) | PAX8HSD17B10CYP2A6TDP1ALDH1A1 | |
| SCHEMBL5133952 | 0.71 | KDM4E (0.38) | HSD17B10TDP1ALDH1A1KDM4EPARP1 | |
| SCHEMBL8661052 | 0.71 | CYP2A6 (0.46) | PAX8HSD17B10CYP2A6TDP1ALDH1A1 | |
| SCHEMBL4709428 | 0.69 | GSTP1 (0.36) | HSD17B10CYP2A6ALDH1A1L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4536193-A1 | COMPOSITIONS | Estrenue Pty Ltd (AU) | 2025-04-16 | — | — | EP | disclosed |
| CN-119816300-A | Composition and method for producing the same | 埃斯特雷努埃私人有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-118772223-A | Compositions and methods for treating central nervous system disorders | 萨奇治疗股份有限公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-111741965-B | Compositions and methods for treating central nervous system disorders | 萨奇治疗股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-118206604-A | Synthesis method of monovalent gold catalyzed 1, 3-diene-1-carbonyl derivative | 沈阳药科大学 | 2024-06-18 | — | — | CN | disclosed |
| WO-2023235935-A1 | COMPOSITIONS | •ESTRENUE PTY LTD (AU) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023143400-A1 | STEROID COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 珂阑(上海)医药科技有限公司 | 2023-08-03 | — | — | WO | disclosed |
| CN-116514892-A | Steroid compound, preparation method and application thereof | 珂阑(上海)医药科技有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-115448823-A | Method for catalyzing allylic oxidation of olefin by heterogeneous iron catalyst | 华中科技大学 | 2022-12-09 | — | — | CN | disclosed |
| EP-1175383-B1 | GLUCOCORTICOID RECEPTOR MODULATORS | PFIZER PROD INC (US) | 2018-03-14 | — | — | EP | disclosed |
| US-7166593-B2 | Glucocorticoid receptor modulators | PFIZER, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1399406-B1 | NOVEL ESTROGEN RECEPTOR LIGANDS AND METHODS I | KAROBIO AB (SE) | 2005-08-10 | — | — | EP | disclosed |
| EP-1501835-A2 | 2-(QUINOLONYL)-FUSED HETEROCYCLES AS ANDROGEN RECEPTOR MODULATORS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040176595-A1 | Glucocorticoid receptor modulators | PFIZER, INC. | 2004-09-09 | — | — | US | disclosed |
| US-6699893-B2 | DIETETICS; ANTIDIABETIC AGENTS; ANTIINFLAMMATROY AGENTS | PFIZER INC | 2004-03-02 | — | — | US | disclosed |
| WO-2003090672-A2 | 2-(QUINOLONYL)-FUSED HETEROCYCLES AS ANDROGEN RECEPTOR MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| US-20020147336-A1 | Glucocorticoid receptor modulators | DOW ROBERT L (US) | 2002-10-10 | — | — | US | disclosed |
| US-6380223-B1 | FOR THERAPY OF DISEASES, SUCH AS OBESITY, DIABETES, INFLAMMATION | PFIZER INC. | 2002-04-30 | — | — | US | disclosed |
| EP-1175383-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | Pfizer Products Inc. (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000066522-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | PFIZER PRODUCTS INC. (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176595-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | PAX8 3268/4885HSD17B10 326/4885CYP2A6 552/4885 |
| US-20020147336-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | PAX8 3251/4885HSD17B10 328/4885CYP2A6 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.